The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target
Table 1
Characteristics of the study population*.
Characteristic
Seropositive ()
Seronegative ()
Controls ()
values
Age
59.4 (33.2–90.4)
60.2 (32.7–80.9)
56.3 (22.4–84.8)
0.87
% Male
50
46.7
53.3
0.94
Lymphocytes†
1.94 (0.84–3.26)
1.95 (0.67–3.18)
2.1 (1.0–3.24)
0.95
% CD4+
50.2 (26.8–66.9)
56.2 (37.6–68.3)
44.43 (28.5–65.4)
0.02
% CD8+
22.3 (8.21–59.1)
17.3 (4.53–51.4)
25.97 (11.2–39.6)
0.03
CRP (mg/L)
33.7 (2–132)
30.29 (2–101)
N/A
0.86
ESR (mm/hr)
24.8 (2–105)
22.2 (1–84)
N/A
0.75
Creatinine (mol/L)
80.4 (49.3–105.2)
82.8 (50.4–139.7)
N/A
0.95
DAS-28 (CRP)
4.20 (0.97–6.66)
4.74 (2.10–8.63)
N/A
0.84
Duration of RA
52.6 (1–232)
46.5 (1–135)
N/A
0.87
Steroid therapy
6/20
6/15
N/A
0.72
DMARD therapy
16/20
9/15
N/A
0.14
Anti-TNF therapy‡
9/20
6/15
N/A
0.77
*values shown are the mean and range (brackets). †106/mL. ‡5 patients received etanercept (3 in the seropositive and 2 in the seronegative group); the remaining patients received adalimumab.
